ArticleBMJ open2026

Implications of relying on manufacturer patient support programs for access to high-cost specialty and biologic medicines: a critical qualitative study.

Quinn Grundy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.